奥扎格雷钠联合依达拉奉治疗急性脑梗死的临床疗效及安全性

The Efficacy and Safety of Ozagrel Sodium Combined with Edaravone in Patients with Acute Cerebral Infarction

目的观察奥扎格雷钠联合依达拉奉治疗急性脑梗死(ACI)的疗效和安全性。方法选择发病在48h内的ACI患者82例,随机分成治疗组(42例)和对照组(40例)。治疗组给予奥扎格雷钠80mg+生理盐水100ml,Bid,同时给予依达拉奉30mg加入生理盐水100ml静脉滴注,Bid,连用14d;对照组仅用同剂量、同疗程的奥扎格雷钠。依据美国国立卫生院卒中量表(NIHSS)评分及日常生活能力(BI)评分评定神经功能缺损程度,并监测肝肾功能、血尿常规及心电图。结果治疗组与对照组相比,NIHSS评分在治疗后一周差异即具有显著性(P<0.05),治疗后2周时差异更显著(P<0.01),而BI分值在治疗后1周和2周时差异具有显著性(P<0.05),治疗后3周时差异更显著(P<0.01)。两组均未见明显不良反应。结论奥扎格雷钠和依达拉奉联合治疗ACI患者疗效较好,安全性好。

Objective To investigate the efficacy and safety of Ozagrel sodium combined with Edaravone in patients with acute cerebral infarction(ACI). Methods Eighty-two ACI patients within 48 hours of onset were enrolled. They were randomly divided into treatment group (42cases) and control group (40 cases). The treatment group was allocated Ozagrel sodium 80mg, Bid, for 14 days and Edaravone 30mg, Bid, for 14 days. And control group was only allocated Ozagrel sodium 80mg, Bid, for 14 days. Therapeutic effect was evaluated by the National Institutes of Health Stroke Scale (NIHSS) and the Bathal index (BI). The liver and renal function, blood and urinary routine, and electrocardiogram (ECG) were detected. Results Compared with the control group, there were significant difference after one week (P<0.05) and after two weeks (P<0.01) in the grades of NIHSS of treatment group, and significant difference after one or two weeks (P<0.05) and after three weeks (P<0.01) in the grades of BI of treatment group. There was no side effect in both groups. Conclusion Ozagrel sodium combined with Edaravone is a effective and safe therapy for the ACI patients.